Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Current Deferred Revenue (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Current Deferred Revenue data on record, last reported at $111.9 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 491.47% year-over-year to $111.9 million; the TTM value through Sep 2025 reached $111.9 million, up 491.47%, while the annual FY2024 figure was $16.1 million, 50.04% down from the prior year.
  • Current Deferred Revenue reached $111.9 million in Q3 2025 per GLUE's latest filing, up from $8.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $111.9 million in Q3 2025 and bottomed at $8.1 million in Q2 2025.
  • Average Current Deferred Revenue over 3 years is $32.5 million, with a median of $20.0 million recorded in 2024.
  • The widest YoY moves for Current Deferred Revenue: up 491.47% in 2025, down 58.98% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $32.3 million in 2023, then plummeted by 50.04% to $16.1 million in 2024, then soared by 592.97% to $111.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $111.9 million in Q3 2025, $8.1 million in Q2 2025, and $32.6 million in Q1 2025.